Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-06-18
Target enrollment:
Participant gender:
Summary
This is a phase III, multicenter, double-blinded, placebo-controlled study of
platinum（Cisplatin or Carboplatin） plus etoposide with or without toripalimab as first Line
therapy in patients with extensive stage small cell lung cancer.
The purpose of this study is to evaluate the safety and efficacy of toriplimab in combination
with platinum（Cisplatin or Carboplatin） plus etoposide in treatment naive extensive stage
small cell lung cancer.
Participants will receive asigned study treatment until progressive disease (PD) as assessed
by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST
v1.1).